Expression of cyclooxygenase-2, p53 and Ki-67 in gastric cancer

Journal of Korean Medical Science

Volumn 21, Issue 5, 2006, Pages 871-876

  Joo, Young Eun ^a   Chung, Ik Joo ^a   Park, Young Kyu ^a   Koh, Yang Seok ^a   Lee, Jae Hyuk ^a   Park, Chang Hwan ^a   Lee, Wan Sik ^a   Kim, Hyun Soo ^a   Choi, Sung Kyu ^a   Rew, Jong Sun ^a   Park, Chang Soo ^a   Kim, Sei Jong ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Cell proliferation; Cyclooxygenase 2; Immunohistochemistry; Stomach neoplasms; Tumor suppressor protein p53

Indexed keywords

EID: 33750260884     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2006.21.5.871     Document Type: Article

References (33)

1. DuBois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063-73.
2. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120.
3. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993; 268: 9049-54.
4. Xie W, Herschman HR. Transcriptional regulation of prostaglandin synthase 2 gene expression by platelet-derived growth factor and serum. J Biol Chem 1996; 271: 31742-8.
5. Sheng H, Williams CS, Shao J, Liang P, DuBois RN, Beauchamp RD. Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. J Biol Chem 1998; 273: 22120-7.
6. Joo YE, Kim HS, Min SW, Lee WS, Park CH, Park CS, Choi SK, Rew JS, Kim SJ. Expression of cyclooxygenase-2 protein in colorectal carcinomas. Int J Gastrointest Cancer 2002; 31: 147-54.
7. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999; 59: 198-204.
8. Joo YE, Oh WT, Rew JS, Park CS, Choi SK, Kim SJ. Cyclooxygenase-2 expression is associated with well-differentiated and intestinal-type pathways in gastric carcinogenesis. Digestion 2002; 66: 222-9.
9. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, Subbaramaiah K. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001; 2: 544-51.
10. Thun MJ. NSAID use and decreased risk of gastrointestinal cancers. Gastroenterol Clin North Am 1996; 25: 333-48.
11. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
12. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 3336-40.
13. Kambayashi T, Alexander HR, Fong M, Strassmann G. Potential involvement of IL-10 in suppressing tumour-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. J Immunol 1995; 154: 3383-90.
14. Cianchi F, Cortesini C, Bechi P, Fantappie O, Messerini L, Vannacci A, Sardi I, Baroni G, Boddi V, Mazzanti R, Masini E. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001; 121: 1339-47.
15. Joo YE, Rew JS, Seo YH, Choi SK, Kim YJ, Park CS, Kim SJ. Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. J Clin Gastroenterol 2003; 37: 28-33.
16. Weidner N, Moore DH 2nd, Vartanian R. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody. Hum Pathol 1994; 25: 337-42.
17. Chan AO, Luk JM, Hui WM, Lam SK. Molecular biology of gastric carcinoma: From laboratory to bedside. J Gastroenterol Hepatol 1999; 14: 1150-60.
18. Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 1999; 274: 10911-5.
19. Leung WK, To KF, Ng YP, Lee TL, Lau JY, Chan FK, Ng EK, Chung SC, Sung JJ. Association between cyclooxygenase-2 overexpression and missense p53 mutations in gastric cancer. Br J Cancer 2001; 84: 335-9.
20. Fleming ID. American Joint Committee on Cancer Classification (AJCC). AJCC cancer staging manual. Philadelphia, Lippincott-Raven, 1997: 71-6.
21. Reed JA, Manahan LJ, Park CS, Brigati DJ. Complete one-hour immunocytochemistry based on capillary action. Biotechniques 1992; 13: 434-43.
22. Yamagishi M, Noda M, Tatsumi Y, Mukaisho K, Mitsufuji S, Sugihara H, Okanoue T, Hattori T. Correlation between cyclooxygenase-2, proliferative activity, and mucin phenotype in human advanced gastric cancer. J Gastroenterol 2004; 39: 1143-9.
23. Sawaoka H, Kawano S, Tsuji S, Tsujii M, Murata H, Hori M. Effects of NSAIDs on proliferation of gastric cancer cells in vitro: possible implication of cyclooxygenase-2 in cancer development. J Clin Gastroenterol 1998; 27 (Suppl 1): 47-52.
24. Mack DH, Vartikar J, Pipas JM, Laimins LA. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature 1993; 363: 281-3.
25. Prives C, Hall PA. The p53 pathway. J Pathol 1999; 187: 112-26.
26. Chen G, Burger MM. p150 overexpression in gastric carcinoma: the association with p53, apoptosis and cell proliferation. Int J Cancer 2004; 112: 393-8.
27. Ishii HH, Gobe GC, Pan W, Yoneyama J, Ebihara Y. Apoptosis and cell proliferation in the development of gastric carcinomas: associations with c-myc and p53 protein expression. J Gastroenterol Hepatol 2002; 17: 966-72.
28. Murata H, Kawano S, Tsuji S, Tsuji M, Sawaoka H, Kimura Y, Shiozaki H, Hori M. Cyclooxygenase 2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999; 94: 451-5.
29. Lim HY, Joo HJ, Choi JH, Yi JW, Yang MS, Cho DY, Kim HS, Nam DK, Lee KB, Kim HC. Increased expression of cyclooxygenase 2 protein in human gastric carcinoma. Clin Cancer Res 2000; 6: 519-25.
30. Igarashi N, Takahashi M, Ohkubo H, Omata K, Iida R, Fujimoto S. Predictive value of Ki-67, p53 protein, and DNA content in the diagnosis of gastric carcinoma. Cancer 1999; 86: 1449-54.
31. Kakeji Y, Korenaga D, Tsujitani S, Baba H, Anai H, Maehara Y, Sugimachi K. Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer 1993; 67: 589-93.
32. Liu XP, Tsushimi K, Tsushimi M, Kawauchi S, Oga A, Furuya T, Sasaki K. Expression of p21 (WAF1/CIP1) and p53 proteins in gastric carcinoma: its relationships with cell proliferation activity and prognosis. Cancer Lett 2001; 170: 183-9.
33. Kanai T, Konno H, Maruyama K, Baba M, Tanaka T, Maruo Y, Nishino N, Nakamura S, Baba S, Sugimura H. p53 overexpression and proliferative activity do not correlate with lymph node metastasis in early gastric cancer. Eur Surg Res 1997; 29: 35-41.